CYP24A1: Structure, function, and physiological role

Vitamin D

Volumn , Issue , 2011, Pages 43-56

  St Arnaud, René ^a,b  

^a SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858038013     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10004-6     Document Type: Chapter

References (152)

1. Omdahl J.L., Morris H.A., May B.K. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu. Rev. Nutr 2002, 22:139-166.
2. Sakaki T., Sawada N., Komai K., Shiozawa S., Yamada S., Yamamoto K., et al. Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur. J. Biochem./FEBS 2000, 267:6158-6165.
3. Tanaka Y., Castillo L., DeLuca H.F. The 24-hydroxylation of 1,25-dihydroxyvitamin D3. J. Biol. Chem 1977, 252:1421-1424.
4. Tanaka Y., DeLuca H.F. Stimulation of 24,25-dihydroxyvitamin D3 production by 1,25-dihydroxyvitamin D3. Science 1974, 183:1198-1200.
5. Napoli J.L., Horst R.L. C(24)- and C(23)-oxidation, converging pathways of intestinal 1,25-dihydroxyvitamin D3 metabolism: identification of 24-keto-1,23,25-trihydroxyvitamin D3. Biochemistry 1983, 22:5848-5853.
6. Ohnuma N., Norman A.W. Identification of a new C-23 oxidation pathway of metabolism for 1,25-dihydroxyvitamin D3 present in intestine and kidney. J. Biol. Chem 1982, 257:8261-8271.
7. Takasaki Y., Suda T., Yamada S., Takayama H., Nishii Y. Isolation, identification, and biological activity of 25-hydroxy-24-oxovitamin D3: a new metabolite of vitamin D3 generated by in vitro incubations with kidney homogenates. Biochemistry 1981, 20:1681-1686.
8. Jones G., Kano K., Yamada S., Furusawa T., Takayama H., Suda T. Identification of 24,25,26,27-tetranor-23-hydroxyvitamin D3 as a product of the renal metabolism of 24,25-dihydroxyvitamin D3. Biochemistry 1984, 23:3749-3754.
9. Makin G., Lohnes D., Byford V., Ray R., Jones G. Target cell metabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation. Biochem. J 1989, 262:173-180.
10. Reddy G.S., Tserng K.Y. Calcitroic acid, end product of renal metabolism of 1,25-dihydroxyvitamin D3 through C-24 oxidation pathway. Biochemistry 1989, 28:1763-1769.
11. Esvelt R.P., Schnoes H.K., DeLuca H.F. Isolation and characterization of 1 alpha-hydroxy-23-carboxytetranorvitamin D: a major metabolite of 1,25-dihydroxyvitamin D3. Biochemistry 1979, 18:3977-3983.
12. Masuda S., Strugnell S., Calverley M.J., Makin H.L., Kremer R., Jones G. In vitro metabolism of the anti-psoriatic vitamin D analog, calcipotriol, in two cultured human keratinocyte models. J. Biol. Chem 1994, 269:4794-4803.
13. Tomon M., Tenenhouse H.S., Jones G. Expression of 25-hydroxyvitamin D3-24-hydroxylase activity in Caco-2 cells. An in vitro model of intestinal vitamin D catabolism. Endocrinology 1990, 126:2868-2875.
14. Reinhardt T.A., Horst R.L. Self-induction of 1,25-dihydroxyvitamin D3 metabolism limits receptor occupancy and target tissue responsiveness. J. Biol. Chem 1989, 264:15917-15921.
15. Horst R.L. 25-OHD3-26,23-lactone: a metabolite of vitamin D3 that is 5 times more potent than 25-OHD3 in the rat plasma competitive protein binding radioassay. Biochem. Biophys. Res. Commun 1979, 89:286-293.
16. Wichmann J.K., DeLuca H.F., Schnoes H.K., Horst R.L., Shepard R.M., Jorgensen N.A. 25-Hydroxyvitamin D3 26,23-lactone: a new in vivo metabolite of vitamin D. Biochemistry 1979, 18:4775-4780.
17. Napoli J.L., Pramanik B.C., Partridge J.J., Uskokovic M.R., Horst R.L. 23S,25-Dihydroxyvitamin D3 as a circulating metabolite of vitamin D3. Its role in 25-hydroxyvitamin D3-26,23-lactone biosynthesis. J. Biol. Chem 1982, 257:9634-9639.
18. Napoli J.L., Horst R.L. (23S)-1,23,25-Trihydroxycholecalciferol, an intestinal metabolite of 1,25-dihydroxycholecalciferol. Biochem. J 1983, 214:261-264.
19. Horst R.L., Wovkulich P.M., Baggiolini E.G., Uskokovic M.R., Engstrom G.W., Napoli J.L. (23S)-1,23,25-Trihydroxyvitamin D3: its biologic activity and role in 1 alpha,25-dihydroxyvitamin D3 26,23-lactone biosynthesis. Biochemistry 1984, 23:3973-3979.
20. Ishizuka S., Yamaguchi H., Yamada S., Nakayama K., Takayama H. Stereochemistry of 25-hydroxyvitamin D3-26,23-lactone and 1 alpha, 25-dihydroxyvitamin D3-26,23-lactone in rat serum. FEBS Lett 1981, 134:207-211.
21. Engstrom G.W., Reinhardt T.A., Horst R.L. 25-Hydroxyvitamin D3-23-hydroxylase, a renal enzyme in several animal species. Arch. Biochem. Biophys 1986, 250:86-93.
22. Akiyoshi-Shibata M., Sakaki T., Ohyama Y., Noshiro M., Okuda K., Yabusaki Y. Further oxidation of hydroxycalcidiol by calcidiol 24-hydroxylase. A study with the mature enzyme expressed in Escherichia coli. Eur. J. Biochem./FEBS 1994, 224:335-343.
23. Beckman M.J., Tadikonda P., Werner E., Prahl J., Yamada S., DeLuca H.F. Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry 1996, 35:8465-8472.
24. Sakaki T., Sawada N., Nonaka Y., Ohyama Y., Inouye K. Metabolic studies using recombinant escherichia coli cells producing rat mitochondrial CYP24 CYP24 can convert 1alpha,25-dihydroxyvitamin D3 to calcitroic acid. Eur. J. Biochem./FEBS 1999, 262:43-48.
25. Pedersen J.I., Hagenfeldt Y., Bjorkhem I. Assay and properties of 25-hydroxyvitamin D3 23-hydroxylase. Evidence that 23,25-dihydroxyvitamin D3 is a major metabolite in 1,25-dihydroxyvitamin D3-treated or fasted guinea pigs. Biochem. J 1988, 250:527-532.
26. Simboli-Campbell M., Jones G. Dietary phosphate deprivation increases renal synthesis and decreases renal catabolism of 1,25-dihydroxycholecalciferol in guinea pigs. J. Nutr 1991, 121:1635-1642.
27. Prosser D.E., Kaufmann M., O'Leary B., Byford V., Jones G. Single A326G mutation converts human CYP24A1 from 25-OH-D3-24-hydroxylase into -23-hydroxylase, generating 1alpha,25-(OH)2D3-26,23-lactone. Proc. Natl. Acad. Sci. USA 2007, 104:12673-12678.
28. Toell A., Gonzalez M.M., Ruf D., Steinmeyer A., Ishizuka S., Carlberg C. Different molecular mechanisms of vitamin D(3) receptor antagonists. Mol. Pharmacol 2001, 59:1478-1485.
29. Ishizuka S., Kurihara N., Reddy S.V., Cornish J., Cundy T., Roodman G.D. (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease. Endocrinology 2005, 146:2023-2030.
30. Ohyama Y., Hayashi S., Okuda K. Purification of 25-hydroxyvitamin D3 24-hydroxylase from rat kidney mitochondria. FEBS Lett 1989, 255:405-408.
31. Ohyama Y., Okuda K. Isolation and characterization of a cytochrome P-450 from rat kidney mitochondria that catalyzes the 24-hydroxylation of 25-hydroxyvitamin D3. J. Biol. Chem 1991, 266:8690-8695.
32. Ohyama Y., Noshiro M., Okuda K. Cloning and expression of cDNA encoding 25-hydroxyvitamin D3 24-hydroxylase. FEBS Lett 1991, 278:195-198.
33. Chen K.S., DeLuca H.F. Cloning of the human 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim. Biophys. Acta 1995, 1263:1-9.
34. Hahn C.N., Kerry D.M., Omdahl J.L., May B.K. Identification of a vitamin D responsive element in the promoter of the rat cytochrome P450(24) gene. Nucleic Acids Res 1994, 22:2410-2416.
35. Ohyama Y., Noshiro M., Eggertsen G., Gotoh O., Kato Y., Bjorkhem I., et al. Structural characterization of the gene encoding rat 25-hydroxyvitamin D3 24-hydroxylase. Biochemistry 1993, 32:76-82.
36. Yamada S., Nakayama K., Takayama H., Shinki T., Takasaki Y., Suda T. Isolation, identification, and metabolism of (23S,25R)-25-hydroxyvitamin D3 26,23-lactol. A biosynthetic precursor of (23S,25R)-25-hydroxyvitamin D3 26,23-lactone. J. Biol. Chem 1984, 259:884-889.
37. Ishizuka S., Norman A.W. Metabolic pathways from 1 alpha,25-dihydroxyvitamin D3 to 1 alpha,25-dihydroxyvitamin D3-26,23-lactone. Stereo-retained and stereo-selective lactonization. J. Biol. Chem 1987, 262:7165-7170.
38. Reinhardt T.A., Horst R.L. Ketoconazole inhibits self-induced metabolism of 1,25-dihydroxyvitamin D3 and amplifies 1,25-dihydroxyvitamin D3 receptor up-regulation in rat osteosarcoma cells. Arch. Biochem. Biophys 1989, 272:459-465.
39. St-Arnaud R., Arabian A., Travers R., Barletta F., Raval-Pandya M., Chapin K., et al. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 2000, 141:2658-2666.
40. St-Arnaud R. Targeted inactivation of vitamin D hydroxylases in mice. Bone 1999, 25:127-129.
41. Masuda S., Byford V., Arabian A., Sakai Y., Demay M.B., St-Arnaud R., et al. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology 2005, 146:825-834.
42. Endres B., Kato S., DeLuca H.F. Metabolism of 1alpha,25-dihydroxyvitamin D(3) in vitamin D receptor-ablated mice in vivo. Biochemistry 2000, 39:2123-2129.
43. Annalora A.J., Goodin D.B., Hong W.X., Zhang Q., Johnson E.F., Stout C.D. Crystal structure of CYP24A1, a mitochondrial cytochrome P450 involved in vitamin D metabolism. J. Mol. Biol 2010, 396:441-451.
44. Kahraman M., Sinishtaj S., Dolan P.M., Kensler T.W., Peleg S., Saha U., et al. Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxyvitamin D(3). J. Med. Chem 2004, 47:6854-6863.
45. Schuster I., Egger H., Nussbaumer P., Kroemer R.T. Inhibitors of vitamin D hydroxylases: structure-activity relationships. J. Cell Biochem 2003, 88:372-380.
46. Schuster I., Egger H., Reddy G.S., Vorisek G. Combination of vitamin D metabolites with selective inhibitors of vitamin D metabolism. Recent Results Cancer Res 2003, 164:169-188.
47. Schuster I., Egger H., Herzig G., Reddy G.S., Schmid J.A., Schussler M., et al. Selective inhibitors of vitamin D metabolism - new concepts and perspectives. Anticancer Res 2006, 26:2653-2668.
48. Hasemann C.A., Kurumbail R.G., Boddupalli S.S., Peterson J.A., Deisenhofer J. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 1995, 3:41-62.
49. Annalora A., Bobrovnikova-Marjon E., Serda R., Lansing L., Chiu M.L., Pastuszyn A., et al. Rat cytochrome P450C24 (CYP24A1) and the role of F249 in substrate binding and catalytic activity. Arch. Biochem. Biophys 2004, 425:133-146.
50. Annalora A.J., Bobrovnikov-Marjon E., Serda R., Pastuszyn A., Graham S.E., Marcus C.B., et al. Hybrid homology modeling and mutational analysis of cytochrome P450C24A1 (CYP24A1) of the Vitamin D pathway: insights into substrate specificity and membrane bound structure-function. Arch. Biochem. Biophys 2007, 460:262-273.
51. Gomaa M.S., Simons C., Brancale A. Homology model of 1alpha,25-dihydroxyvitamin D3 24-hydroxylase cytochrome P450 24A1 (CYP24A1): active site architecture and ligand binding. J. Steroid. Biochem. Mol. Biol 2007, 104:53-60.
52. Hamamoto H., Kusudo T., Urushino N., Masuno H., Yamamoto K., Yamada S., et al. Structure-function analysis of vitamin D 24-hydroxylase (CYP24A1) by site-directed mutagenesis: amino acid residues responsible for species-based difference of CYP24A1 between humans and rats. Mol. Pharmacol 2006, 70:120-128.
53. Masuda S., Prosser D.E., Guo Y.D., Kaufmann M., Jones G. Generation of a homology model for the human cytochrome P450, CYP24A1, and the testing of putative substrate binding residues by site-directed mutagenesis and enzyme activity studies. Arch. Biochem. Biophys 2007, 460:177-191.
54. Omdahl J.L., Swamy N., Serda R., Annalora A., Berne M., Rayb R. Affinity labeling of rat cytochrome P450C24 (CYP24) and identification of Ser57 as an active site residue. J. Steroid Biochem. Mol. Biol 2004, 89-90:159-162.
55. Urushino N., Yamamoto K., Kagawa N., Ikushiro S., Kamakura M., Yamada S., et al. Interaction between mitochondrial CYP27B1 and adrenodoxin: role of arginine 458 of mouse CYP27B1. Biochemistry 2006, 45:4405-4412.
56. Boyan B.D., Sylvia V.L., Dean D.D., Del Toro F., Schwartz Z. Differential regulation of growth plate chondrocytes by 1alpha,25-(OH)2D3 and 24R,25-(OH)2D3 involves cell-maturation-specific membrane-receptor-activated phospholipid metabolism. Crit. Rev. Oral. Biol. Med 2002, 13:143-154.
57. Boyan B.D., Jennings E.G., Wang L., Schwartz Z. Mechanisms regulating differential activation of membrane-mediated signaling by 1alpha,25(OH)2D3 and 24R,25(OH)2D3. J. Steroid. Biochem. Mol. Biol 2004, 89-90:309-315.
58. Atsumi T., Miwa Y., Kimata K., Ikawa Y. A chondrogenic cell line derived from a differentiating culture of AT805 teratocarcinoma cells. Cell Differ. Dev 1990, 30:109-116.
59. Denison T.A., Koch C.F., Shapiro I.M., Schwartz Z., Boyan B.D. Inorganic phosphate modulates responsiveness to 24,25(OH)2D3 in chondrogenic ATDC5 cells. J. Cell Biochem 2009, 107:155-162.
60. Schwartz Z., Sylvia V.L., Luna M.H., DeVeau P., Whetstone R., Dean D.D., et al. The effect of 24R,25-(OH)(2)D(3) on protein kinase C activity in chondrocytes is mediated by phospholipase D whereas the effect of 1alpha,25-(OH)(2)D(3) is mediated by phospholipase C. Steroids 2001, 66:683-694.
61. Maeda S., Dean D.D., Sylvia V.L., Boyan B.D., Schwartz Z. Metalloproteinase activity in growth plate chondrocyte cultures is regulated by 1,25-(OH)(2)D(3) and 24,25-(OH)(2)D(3) and mediated through protein kinase C. Matrix Biol 2001, 20:87-97.
62. Dean D.D., Schwartz Z., Schmitz J., Muniz O.E., Lu Y., Calderon F., et al. Vitamin D regulation of metalloproteinase activity in matrix vesicles. Connect. Tissue Res 1996, 35:331-336.
63. Dean D.D., Boyan B.D., Schwartz Z., Muniz O.E., Carreno M.R., Maeda S., et al. Effect of 1alpha,25-dihydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3 on metalloproteinase activity and cell maturation in growth plate cartilage in vivo. Endocrine 2001, 14:311-323.
64. Boyan B.D., Sylvia V.L., Dean D.D., Schwartz Z. 24,25-(OH)(2)D(3) regulates cartilage and bone via autocrine and endocrine mechanisms. Steroids 2001, 66:363-374.
65. Sylvia V.L., Schwartz Z., Del Toro F., DeVeau P., Whetstone R., Hardin R.R., et al. Regulation of phospholipase D (PLD) in growth plate chondrocytes by 24R,25-(OH)2D3 is dependent on cell maturation state (resting zone cells) and is specific to the PLD2 isoform. Biochim. Biophys. Acta 2001, 1499:209-221.
66. Hurst-Kennedy J., Boyan B.D., Schwartz Z. Lysophosphatidic acid signaling promotes proliferation, differentiation, and cell survival in rat growth plate chondrocytes. Biochim. Biophys. Acta 2009, 1793:836-846.
67. 3-responsive phenotype characteristic of growth zone chondrocytes. Endocrinology 1995, 136:402-411.
68. St-Arnaud R. Mutant mouse models of vitamin D metabolic enzymes. Vitamin D 2005, 105-116. Elsevier Academic Press, San Diego. second ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
69. Garland C.F., Garland F.C. Do sunlight and vitamin D reduce the likelihood of colon cancer?. Int. J. Epidemiol 1980, 9:227-231.
70. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 2007, 7:684-700.
71. Zinser G.M., McEleney K., Welsh J. Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice. Mol. Cell Endocrinol 2003, 200:67-80.
72. Hahn C.N., Baker E., Laslo P., May B.K., Omdahl J.L., Sutherland G.R. Localization of the human vitamin D 24-hydroxylase gene (CYP24) to chromosome 20q13.2->q13.3. Cytogenet. Cell Genet 1993, 62:192-193.
73. Albertson D.G., Ylstra B., Segraves R., Collins C., Dairkee S.H., Kowbel D., et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet 2000, 25:144-146.
74. Fukushige S., Waldman F.M., Kimura M., Abe T., Furukawa T., Sunamura M., et al. Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 1997, 19:161-169.
75. Korn W.M., Yasutake T., Kuo W.L., Warren R.S., Collins C., Tomita M., et al. Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer 1999, 25:82-90.
76. Meijer G.A., Hermsen M.A., Baak J.P., van Diest P.J., Meuwissen S.G., Belien J.A., et al. Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. J. Clin. Pathol 1998, 51:901-909.
77. Sonoda G., Palazzo J., du Manoir S., Godwin A.K., Feder M., Yakushiji M., et al. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer 1997, 20:320-328.
78. Weiss M.M., Snijders A.M., Kuipers E.J., Ylstra B., Pinkel D., Meuwissen S.G., et al. Determination of amplicon boundaries at 20q13.2 in tissue samples of human gastric adenocarcinomas by high-resolution microarray comparative genomic hybridization. J. Pathol 2003, 200:320-326.
79. Werner M., Mattis A., Aubele M., Cummings M., Zitzelsberger H., Hutzler P., et al. 20q13.2 amplification in intraductal hyperplasia adjacent to in situ and invasive ductal carcinoma of the breast. Virchows. Arch 1999, 435:469-472.
80. Tanner M.M., Grenman S., Koul A., Johannsson O., Meltzer P., Pejovic T., et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin. Cancer Res 2000, 6:1833-1839.
81. Wolter H., Gottfried H.W., Mattfeldt T. Genetic changes in stage pT2N0 prostate cancer studied by comparative genomic hybridization. BJU. Int 2002, 89:310-316.
82. Hogarty M.D., Brodeur G.M. Gene amplification in human cancers: biological and clinical significance. The Genetic Basis of Human Cancer 2002, 115-128. McGraw-Hill, New York. second ed. B. Vogelstein, K.W. Kinzler (Eds.).
83. Mimori K., Tanaka Y., Yoshinaga K., Masuda T., Yamashita K., Okamoto M., et al. Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann. Oncol 2004, 15:236-241.
84. Reichrath J., Rafi L., Rech M., Mitschele T., Meineke V., Gartner B.C., et al. Analysis of the vitamin D system in cutaneous squamous cell carcinomas. J. Cutan. Pathol 2004, 31:224-231.
85. Mitschele T., Diesel B., Friedrich M., Meineke V., Maas R.M., Gartner B.C., et al. Analysis of the vitamin D system in basal cell carcinomas (BCCs). Lab. Invest 2004, 84:693-702.
86. Anderson M.G., Nakane M., Ruan X., Kroeger P.E., Wu-Wong J.R. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother. Pharmacol 2006, 57:234-240.
87. Cross H.S., Bises G., Lechner D., Manhardt T., Kallay E. The Vitamin D endocrine system of the gut - its possible role in colorectal cancer prevention. J. Steroid Biochem. Mol. Biol 2005, 97:121-128.
88. Parise R.A., Egorin M.J., Kanterewicz B., Taimi M., Petkovich M., Lew A.M., et al. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int. J. Cancer 2006, 119:1819-1828.
89. Jones G., Ramshaw H., Zhang A., Cook R., Byford V., White J., et al. Expression and activity of vitamin D-metabolizing cytochrome P450s (CYP1alpha and CYP24) in human nonsmall cell lung carcinomas. Endocrinology 1999, 140:3303-3310.
90. Lou Y.R., Qiao S., Talonpoika R., Syvala H., Tuohimaa P. The role of Vitamin D3 metabolism in prostate cancer. J. Steroid Biochem. Mol. Biol 2004, 92:317-325.
91. Miller G.J., Stapleton G.E., Hedlund T.E., Moffat K.A. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res 1995, 1:997-1003.
92. Yee S.W., Campbell M.J., Simons C. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. J. Steroid Biochem. Mol. Biol 2006, 98:228-235.
93. Malas S., Peters J., Abbott C. The genes for endothelin 3, vitamin D 24-hydroxylase, and melanocortin 3 receptor map to distal mouse chromosome 2, in the region of conserved synteny with human chromosome 20. Mamm. Genome 1994, 5:577-579.
94. Hodgson G., Hager J.H., Volik S., Hariono S., Wernick M., Moore D., et al. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat. Genet 2001, 29:459-464.
95. Chung I., Karpf A.R., Muindi J.R., Conroy J.M., Nowak N.J., Johnson C.S., et al. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. J. Biol. Chem 2007, 282:8704-8714.
96. McCullough M.L., Bostick R.M., Mayo T.L. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu. Rev. Nutr 2009, 29:111-132.
97. Dong L.M., Ulrich C.M., Hsu L., Duggan D.J., Benitez D.S., White E., et al. Vitamin D related genes, CYP24A1 and CYP27B1, and colon cancer risk. Cancer Epidemiol. Biomarkers Prev 2009, 18:2540-2548.
98. Holick C.N., Stanford J.L., Kwon E.M., Ostrander E.A., Nejentsev S., Peters U. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol. Biomarkers Prev 2007, 16:1990-1999.
99. Roff A., Wilson R.T. A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expression. J. Steroid Biochem. Mol. Biol 2008, 112:47-54.
100. 3 in colorectal cancer. J. Steroid Biochem. Mol. Biol 2010, doi: 10.1016/j.jsbmb.2010.03.080.
101. Muindi J.R., Nganga A., Engler K.L., Coignet L.J., Johnson C.S., Trump D.L. CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines. J. Steroid Biochem. Mol. Biol 2007, 103:334-337.
102. Ren S., Nguyen L., Wu S., Encinas C., Adams J.S., Hewison M. Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J. Biol. Chem 2005, 280:20604-20611.
103. Pesole G., Liuni S. Internet resources for the functional analysis of 5' and 3' untranslated regions of eukaryotic mRNAs. Trends Genet 1999, 15:378.
104. Patel U.D., Young E.W., Ojo A.O., Hayward R.A. CKD progression and mortality among older patients with diabetes. Am. J. Kidney Dis 2005, 46:406-414.
105. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis 2002, 39:S1-266.
106. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J. Bone Miner. Res 2002, 17:2094-2105.
107. Martinez I., Saracho R., Montenegro J., Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am. J. Kidney Dis 1997, 29:496-502.
108. Salusky I.B. Are new vitamin D analogues in renal bone disease superior to calcitriol?. Pediatr. Nephrol 2005, 20:393-398.
109. Llach F., Fernandez E. Overview of renal bone disease: causes of treatment failure, clinical observations, the changing pattern of bone lesions, and future therapeutic approach. Kidney Int. Suppl 2003, S113-S119.
110. Slatopolsky E., Gonzalez E., Martin K. Pathogenesis and treatment of renal osteodystrophy. Blood Purif 2003, 21:318-326.
111. Steddon S.J., Fan S.L., Cunningham J. New prospects for the management of renal bone disease. Nephron. Clin. Pract 2005, 99:c1-c7.
112. Goodman W.G., Goldin J., Kuizon B.D., Yoon C., Gales B., Sider D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med 2000, 342:1478-1483.
113. Raggi P., Boulay A., Chasan-Taber S., Amin N., Dillon M., Burke S.K., et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?. J. Am. Coll. Cardiol 2002, 39:695-701.
114. Raggi P., Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol 2008, 3:836-843.
115. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis 2003, 42:S1-201.
116. Drueke T.B. Which vitamin D derivative to prescribe for renal patients. Curr. Opin. Nephrol. Hypertens 2005, 14:343-349.
117. Frazao J.M., Chesney R.W., Coburn J.W. Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group. Nephrol. Dial. Transplant 1998, 13(Suppl. 3):68-72.
118. Frazao J.M., Elangovan L., Maung H.M., Chesney R.W., Acchiardo S.R., Bower J.D., et al. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am. J. Kidney Dis 2000, 36:550-561.
119. Martin K.J., Gonzalez E.A., Gellens M., Hamm L.L., Abboud H., Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J. Am. Soc. Nephrol 1998, 9:1427-1432.
120. Maung H.M., Elangovan L., Frazao J.M., Bower J.D., Kelley B.J., Acchiardo S.R., et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am. J. Kidney Dis 2001, 37:532-543.
121. Helvig C., Kharebov A., Petkovich M., Ryder K., Ireland B., Cuerrier D. The role of CYP24-mediated catabolism on vitamin D status and responsiveness in a rodent model of CKD. J. Bone Miner. Res 2009, (Suppl. 1). Available at, Accessed April 29, 2010. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=df1f 0fcc-a9c8-4c14-9ab6-587adcf72123.
122. Zehnder D., Quinkler M., Eardley K.S., Bland R., Lepenies J., Hughes S.V., et al. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 2008, 74:1343-1353.
123. Posner G.H., Helvig C., Cuerrier D., Collop D., Kharebov A., Ryder K., et al. Vitamin D analogues targeting CYP24 in chronic kidney disease. J. Steroid Biochem. Mol. Biol 2010, doi: 10.1016/j.jsbmb.2010.03.065.
124. Hadjiargyrou M., Lombardo F., Zhao S., Ahrens W., Joo J., Ahn H., et al. Transcriptional profiling of bone regeneration. Insight into the molecular complexity of wound repair. J. Biol. Chem 2002, 277:30177-30182.
125. Hatano H., Siegel H.J., Yamagiwa H., Bronk J.T., Turner R.T., Bolander M.E., et al. Identification of estrogen-regulated genes during fracture healing, using DNA microarray. J. Bone Miner. Metab 2004, 22:224-235.
126. Nakazawa T., Nakajima A., Seki N., Okawa A., Kato M., Moriya H., et al. Gene expression of periostin in the early stage of fracture healing detected by cDNA microarray analysis. J. Orthop. Res 2004, 22:520-525.
127. Rundle C.H., Wang H., Yu H., Chadwick R.B., Davis E.I., Wergedal J.E., et al. Microarray analysis of gene expression during the inflammation and endochondral bone formation stages of rat femur fracture repair. Bone 2006, 38:521-529.
128. Colnot C., Thompson Z., Miclau T., Werb Z., Helms J.A. Altered fracture repair in the absence of MMP9. Development 2003, 130:4123-4133.
129. Ferguson C., Alpern E., Miclau T., Helms J.A. Does adult fracture repair recapitulate embryonic skeletal formation?. Mech. Dev 1999, 87:57-66.
130. Seo E.G., Norman A.W. Three-fold induction of renal 25-hydroxyvitamin D3-24-hydroxylase activity and increased serum 24,25-dihydroxyvitamin D3 levels are correlated with the healing process after chick tibial fracture. J. Bone Miner. Res 1997, 12:598-606.
131. Seo E.G., Einhorn T.A., Norman A.W. 24R,25-dihydroxyvitamin D3: an essential vitamin D3 metabolite for both normal bone integrity and healing of tibial fracture in chicks. Endocrinology 1997, 138:3864-3872.
132. Seo E.G., Kato A., Norman A.W. Evidence for a 24R,25(OH)2-vitamin D3 receptor/binding protein in a membrane fraction isolated from a chick tibial fracture-healing callus. Biochem. Biophys. Res. Commun 1996, 225:203-208.
133. Kato A., Seo E.G., Einhorn T.A., Bishop J.E., Norman A.W. Studies on 24R,25-dihydroxyvitamin D3: evidence for a nonnuclear membrane receptor in the chick tibial fracture-healing callus. Bone 1998, 23:141-146.
134. Aronson J. Experimental and clinical experience with distraction osteogenesis. Cleft Palate Craniofac. J 1994, 31:473-481. Discussion 481-472.
135. Tay B.K., Le A.X., Gould S.E., Helms J.A. Histochemical and molecular analyses of distraction osteogenesis in a mouse model. J. Orthop. Res 1998, 16:636-642.
136. Thompson Z., Miclau T., Hu D., Helms J.A. A model for intramembranous ossification during fracture healing. J. Orthop. Res 2002, 20:1091-1098.
137. Aspenberg P. Drugs and fracture repair. Acta. Orthop 2005, 76:741-748.
138. Holick M.F., Siris E.S., Binkley N., Beard M.K., Khan A., Katzer J.T., et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J. Clin. Endocrinol. Metab 2005, 90:3215-3224.
139. Rucker D., Allan J.A., Fick G.H., Hanley D.A. Vitamin D insufficiency in a population of healthy western Canadians. CMAJ 2002, 166:1517-1524.
140. Thomas M.K., Lloyd-Jones D.M., Thadhani R.I., Shaw A.C., Deraska D.J., Kitch B.T., et al. Hypovitaminosis D in medical inpatients. N. Engl. J. Med 1998, 338:777-783.
141. Loose D.S., Kan P.B., Hirst M.A., Marcus R.A., Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J. Clin. Invest 1983, 71:1495-1499.
142. Farhan H., Wahala K., Cross H.S. Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J. Steroid Biochem. Mol. Biol 2003, 84:423-429.
143. Farhan H., Wahala K., Adlercreutz H., Cross H.S. Isoflavonoids inhibit catabolism of vitamin D in prostate cancer cells. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci 2002, 777:261-268.
144. Farhan H., Cross H.S. Transcriptional inhibition of CYP24 by genistein. Ann. N.Y. Acad. Sci 2002, 973:459-462.
145. Rao A., Woodruff R.D., Wade W.N., Kute T.E., Cramer S.D. Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J. Nutr 2002, 132:3191-3194.
146. Wietzke J.A., Welsh J. Phytoestrogen regulation of a Vitamin D3 receptor promoter and 1,25-dihydroxyvitamin D3 actions in human breast cancer cells. J. Steroid Biochem. Mol. Biol 2003, 84:149-157.
147. Kallay E., Adlercreutz H., Farhan H., Lechner D., Bajna E., Gerdenitsch W., et al. Phytoestrogens regulate vitamin D metabolism in the mouse colon: relevance for colon tumor prevention and therapy. J. Nutr 2002, 132:3490S-3493S.
148. Ingram D., Sanders K., Kolybaba M., Lopez D. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997, 350:990-994.
149. Jacobsen B.K., Knutsen S.F., Fraser G.E. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998, 9:553-557.
150. Swami S., Krishnan A.V., Moreno J., Bhattacharyya R.B., Peehl D.M., Feldman D. Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J. Nutr 2007, 137:205S-210S.
151. Cross H.S., Kallay E., Lechner D., Gerdenitsch W., Adlercreutz H., Armbrecht H.J. Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. J. Nutr 2004, 134:1207S-1212S.
152. Posner G.H., Wang Q., Han G., Lee J.K., Crawford K., Zand S., et al. Conceptually new sulfone analogues of the hormone 1alpha, 25-dihydroxyvitamin D(3): synthesis and preliminary biological evaluation. J. Med. Chem 1999, 42:3425-3435.